College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
Zenomics Inc., Los Angeles, CA, 90095, USA.
Drug Deliv Transl Res. 2022 Feb;12(2):472-483. doi: 10.1007/s13346-021-01073-7. Epub 2021 Oct 12.
Cardiovascular diseases remain a leading cause of global disease burden. To date, the limited drug delivery efficacy confines the therapeutic effect in most conventional approaches, such as intramyocardial injections and vascular devices, due to short-term drug release and low retention within the disease sites. As a typical transdermal medical device with a minimally invasive manner and controlled/sustained drug release pattern, microneedles have gained momentum in the field of cardiovascular therapy, from which several cardiovascular diseases have been benefited to the ultimate therapeutic effects. In this concise review, strategies based on the microneedles for the treatments of cardiovascular diseases are introduced, mainly focus on hypertension, atherosclerosis, thrombus, and myocardial diseases. The limitations at the present stage and perspectives of the next-generation microneedles for cardiovascular therapy are also discussed.
心血管疾病仍然是全球疾病负担的主要原因。迄今为止,由于药物短期释放和在疾病部位的低保留率,大多数传统方法(如心肌内注射和血管装置)的有限药物输送效果限制了治疗效果。作为一种具有微创方式和控制/持续药物释放模式的典型透皮医疗器械,微针在心血管治疗领域引起了关注,几种心血管疾病已经从中受益,达到了最终的治疗效果。在这篇简明的综述中,我们介绍了基于微针的治疗心血管疾病的策略,主要集中在高血压、动脉粥样硬化、血栓和心肌疾病上。还讨论了现阶段的局限性和下一代心血管治疗用微针的前景。